<?xml version="1.0" encoding="UTF-8"?>
<p>Although &lt;2% of coronavirus disease 2019 (COVID-19) infections are reported in the pediatric population, children with comorbidities such as congenital heart disease and those at a younger age are more likely to become critically ill.
 <sup>
  <xref rid="B1" ref-type="bibr">1</xref>
  <xref rid="B2" ref-type="bibr"/>-
  <xref rid="B3" ref-type="bibr">3</xref>
 </sup> Remdesivir has been reported to be efficacious in adults with COVID-19
 <sup>
  <xref rid="B4" ref-type="bibr">4</xref>
 </sup>; however, there are no studies in children. Convalescent plasma (CP) can contain neutralizing antibodies to viruses,
 <sup>
  <xref rid="B5" ref-type="bibr">5</xref>
 </sup> and has been used during previous viral epidemics with clinical improvement.
 <sup>
  <xref rid="B6" ref-type="bibr">6</xref>
  <xref rid="B7" ref-type="bibr"/>
  <xref rid="B8" ref-type="bibr"/>
  <xref rid="B9" ref-type="bibr"/>
  <xref rid="B10" ref-type="bibr"/>-
  <xref rid="B11" ref-type="bibr">11</xref>
 </sup> COVID-19 CP (C19-CP) may be useful in critically ill adults, resulting in improvement in inflammatory markers, pulmonary lesions, and mortality.
 <sup>
  <xref rid="B12" ref-type="bibr">12</xref>
 </sup> However, the impact of C19-CP in pediatric patients, particularly infants with developing immune systems and significant comorbidities, is completely unknown.
</p>
